Consortium to CD3 molecule, including a variable light chain domain (VL) and a variable heavy chain domain (VH), can combine human CD3 with the highest content of non-human papillary animals； drug ingredients containing this molecule； and drug formulation.
The present invention relates to CD3 -binding molecules capable of binding to human and non-human CD3, and in particular to such molecules that are cross-reactive with CD3 of a non-human mammal (e.g., a cynomolgus monkey). The invention also pertains to uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other conditions.MOLÉCULA DE UNION A CD3 QUE COMPRENDE UN DOMINIO VARIABLE DE CADENA LIGERA (VL) Y UN DOMINIO VARIABLE DE CADENA PESADA (VH) CAPAZ DE UNIR UN EPITOPE DE CD3 HUMANO Y DE MAMIFEROS NO HUMANOS； COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DICHA MOLÉCULA； Y USO PARA PREPARAR UN MEDICAMENTO.
